On Tuesday, Pandora Media Inc (NYSE:P)’s shares declined -1.78% to $16.56.
Pandora Media Inc (P) declared that its display inventory is now accessible for programmatic buying across smartphones and tablets. Pandora’s new programmatic solution supplements its desktop offering to deliver viewable inventory, qualified data and a robust, engaged audience at scale across devices.
Pandora’s mobile programmatic solution gives media buyers the opportunity to:
- Reach nearly 80 million active listeners, 80 percent of whom are tuning in via mobile devices.
- Efficiently bid on premium display inventory through private marketplace and preferred deals.
- Leverage Pandora’s registration data, proprietary targeting segments, advertising IDs and / or the advertiser’s own dataset to effectively reach their target audience.
Pandora’s mobile programmatic solution was released in beta in March of 2015 and has been leveraged by brands such as Ford and agencies counting Essence.
Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access free music and comedy catalogs, in addition to offers Pandora One, a paid subscription service to listeners. It also sells audio, display, and video advertising to advertisers for delivery on computer, mobile, and other connected device platforms. As of December 31, 2014, the company had about 250 million registered users; and 81.5 million active users. Pandora Media, Inc. was founded in 2000 and is headquartered in Oakland, California.
XOMA Corp (NASDAQ:XOMA)’s shares dropped -0.54% to $3.66.
XOMA Corp (XOMA) declared XOMA 358, a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism (HI).
Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, in addition to tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance, and waiver of Prescription Drug User Fee Act (PDUFA) filing fees. The OOPD also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
At the end of Tuesday’s trade, Magnum Hunter Resources Corp (NYSE:MHR)‘s shares dipped -3.20% to $1.21.
Magnum Hunter Resources Corp (MHR) declared that it has declared a monthly cash dividend on the Company’s 10.25% Series C Cumulative Perpetual Preferred Stock (“Series C Preferred Stock”), a monthly cash dividend on the Company’s 8.0% Series D Cumulative Preferred Stock and a monthly cash dividend on the Company’s 8.0% Series E Cumulative Convertible Preferred Stock (“Series E Preferred Stock”). The outstanding shares of Series E Preferred Stock are represented by depositary shares (the “Depositary Shares”), each representing a 1/1,000th interest of a share of Series E Preferred Stock.
The dividend on the Series C Preferred Stock, which is for the month of June 2015, is payable on June 30, 2015, to holders of record at the close of business on June 15, 2015. The payment will be an annualized 10.25% per share, which is equivalent to about $0.2135 per share, based on the $25.00 per share liquidation preference of the Series C Preferred Stock. The Series C Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “MHR.PRC”.
The dividend on the Series D Preferred Stock, which is for the month of June 2015, is payable on June 30, 2015, to holders of record at the close of business on June 15, 2015. The payment will be an annualized 8.0% per share, which is equivalent to about $0.3333 per share, based on the $50.00 per share liquidation preference of the Series D Preferred Stock. The Series D Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “MHR.PRD”.
Magnum Hunter Resources Corporation, an independent oil and gas company, explores for, exploits, acquires, develops, and produces crude oil, natural gas, and natural gas liquid resources in the United States. The company operates through the U.S. Upstream, Midstream, and Oilfield Services segments.
International Business Machines Corp. (NYSE:IBM), ended its Tuesday’s trading session with 0.35% gain, and closed at $166.84.
Ongoing to strengthen its global cloud presence in the European market, IBM (NYSE: IBM) has opened its first cloud data center in Italy. Located in Cornaredo, a municipality in the Province of Milan, the new facility provides the fast-growing Italian cloud market with a local IBM Cloud presence, allowing customers to deploy their workloads in the country and benefit from a low-latency connection into IBM Cloud’s global platform, which securely integrates data and applications for clients around the world.
The new IBM Cloud center, powered by SoftLayer infrastructure, allows customers and partners adopting cloud computing to more easily manage, run, and store data and workloads Italy, key for many local clients in regulated industries. Global customers can also use the new facility to reach local end users, create data redundancy, and achieve geographic diversity.
The Milan location supports an emerging cloud-computing market in Italy, which, according to The Polytechnic University of Milan’s Observatory of Cloud and ICT as a Service, saw 31 percent year-over-year growth in 2014, with a total market spend of more than EUR 1.18 billion (US$1.33 billion).
International Business Machines Corporation provides information technology (IT) products and services worldwide. The companys Global Technology Services segment provides IT infrastructure and business process services, such as outsourcing, processing, integrated technology, cloud, and technology support. Its Global Business Services segment offers consulting and systems integration services for strategy and transformation, application innovation services, enterprise applications, and smarter analytics; and application administration, maintenance, and support services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
